ABSTRACT
Existem poucos dados na literatura sobre os resultados obstétricos e oncológicos de adolescentes com tumores borderline de ovário em estádio avançado trata- das com cirurgia preservadora da fertilidade. Uma adolescente de 15 anos com diagnóstico de tumor borderline de ovário estádio IIIc foi inicialmente tratada com tumorectomia ovariana bilateral e quimioterapia adjuvante com esquema de platina/taxano (seis ciclos). Durante o seguimento, foi submetida a outras três tumorectomias devido a tumor borderline de ovário (duas vezes) e cistadenoma ovariano (uma vez). Outra recidiva de tumor borderline de ovário ocorreu seis anos após o diagnóstico inicial, quando ela estava grávida; foi tratada com tumorecto- mia realizada durante a cesariana. Em sua última consulta ambulatorial, a mulher de 27 anos não apresentava evidência da doença e tinha um filho saudável. Mesmo em estádio avançado, a cirurgia de preservação da fertilidade foi segura e factível nessa paciente com tumor borderline de ovário.
There are few data in the literature regarding obstetric and oncological outcomes of adolescents with advanced-stage borderline ovarian tumors treated with fertility spa- ring surgery. A 15 years old adolescent who was diagnosed with a stage IIIc borderline ovarian tumor, was treated with bilateral ovarian tumorectomies and adjuvant chemotherapy with platinum/taxane regimen (six cycles). During follow up she was submitted to other three tumorectomies due to borderline ovarian tumor(twice) and ovarian cysta- denoma (once). Another borderline ovarian tumorrecurren- ce occurred six years after initial diagnosis, when she was pregnant; treated with tumorectomy performed during ce- sarean section. At her last outpatient visit, the 27-year-old woman had no evidence of disease and a had healthy child. Even at an advanced stage, fertility sparing surgery was safe and feasible in this patient with borderline ovarian tumor.
Subject(s)
Humans , Female , Pregnancy , Adolescent , Adult , Ovary/surgery , Fertility Preservation , Carcinoma, Ovarian Epithelial/drug therapy , Ovary/diagnostic imaging , Pregnancy , Women's Health , Adolescent, HospitalizedABSTRACT
Neoadjuvant radiotherapy and chemotherapy combined with surgery is the standard treatment for patients with locally advanced esophageal cancer, which has been widely applied in clinical practice. Clinical efficacy has also been recognized by clinicians. However, even after the completion of neoadjuvant radiotherapy and subsequent surgical treatment, some patients still have local regional recurrence or distant metastasis in a short period of time. Among them, distant metastasis has become the main failure mode of patients undergoing surgery after neoadjuvant radiotherapy and chemotherapy, indicating that this treatment remains to be further improved. Based on the experience of patients with rectal cancer benefiting from total neoadjuvant therapy, the feasibility and implementation of total neoadjuvant therapy for locally advanced esophageal cancer were discussed in this article.
ABSTRACT
Objective:To investigate the safety and dose of 4D template (real-time adjustable angle template) in the treatment of advanced malignant tumors with 125I seeds. Methods:98 patients with advanced malignant tumors admitted to Department of Thoracic Surgery of Shaanxi Provincial Tumor Hospital were treated with 4D template-navigated radioactive 125I seed implantation from June 2018 to December 2019. Preoperative TPS plan, intraoperative optimization, postoperative verification of immediate dose and postoperative evaluation of implantation dose were performed. The treatment results were observed. Results:All 98 patients completed the seed implantation. The implantation dose of GTV of implantation site receiving external irradiation was (12 489±414) cGy and the dose of no external irradiation was (15 036±514) cGy. V 100% was 84.7%-94.1%, and 88.2%-93.7%. The implantation dose of CTV was (7 450±621) cGy, and (9 080±761) cGy. The quality of dose implantation was evaluated as: excellent in 89 cases (91%, 89/98), good in 7 cases (7%, 7/98), fair in 2 cases (2%, 2/98), and poor in 0 case, respectively. The symptom relief rate of patients with pain was 92%(36/39). The 1-and 2-year local control rates were 61%, 36% and 82%, 54% in patients treated with and without external irradiation, respectively. The difference was statistically significant ( P=0.02). The incidence rates of pneumothorax and hemoptysis were 19%(9/48) and 10%(5/48). No corresponding complications were observed in other parts of the patients. Conclusion:4D template-assisted 125I seed therapy is safe and effective for malignant tumors, and intraoperative adjustment of needle angle and dose optimization can realize the precise control of implantation dose.
ABSTRACT
Objective:To investigate the current status of family caregivers learned helplessness in patients with advanced digestive tract tumor and analyze its influencing factors, so as to provide reference for the physical and mental management of cancer families.Methods:Totally 181 family caregivers of advanced digestive tract tumor patients from July 2018 to November 2019 in 4 gradeⅢclass A hospitals in Fuzhou were selected by convenient sampling method for investigation with the general information questionnaire and Learned Helplessness Scale. Multiple linear regression analysis was used to analyze the influencing factors of learned helplessness of family caregivers of patients with advanced digestive tract tumor.Results:The total score and the average items score of learned helplessness was (38.61 ± 15.40), (2.15 ± 0.88) points, which was at a lower level. Multiple linear regression analysis showed that the gender of caregiver, physical condition of caregivers, average monthly household income were significant influencing factors of family caregivers learned helplessness in patients with advanced digestive tract tumor ( P<0.05). Conclusions:The learned helplessness of family caregivers of patients with advanced digestive tract tumor is at a mild level. Nurses should focus on the physical and mental conditions of low-income groups and female caregivers with advanced digestive tract tumor, and regularly assess their nursing needs and health status to improve their quality of life.
ABSTRACT
RESUMEN Introducción: La conducta ante el glaucoma avanzado es polémica entre los oftalmólogos por sus posibles consecuencias visuales. Objetivo: Evaluar el resultado de la trabeculectomía en el tratamiento de pacientes con glaucoma avanzado. Método: En el Hospital General Docente "Dr. Juan Bruno Zayas Alfonso" de Santiago de Cuba, durante el periodo de 2015-2018, se realizó un estudio observacional, descriptivo, longitudinal, de una serie de casos. El universo fue conformado por 57 ojos con glaucoma avanzado operados con la citada técnica. Se describen las variables: edad, sexo, variables en el periodo preoperatorio y posoperatorio (cantidad de fármacos para el control del glaucoma, agudeza visual mejor corregida, campo visual, medición de la presión intraocular, complicaciones posoperatorias). Resultados: La edad promedio fue de 65,4 años, el 55,8 % eran hombres. La agudeza visual posoperatoria fue la misma que la preoperatoria en 54 ojos (96,5 %). La medicación antiglaucoma disminuyó a un valor medio de 1,6 fármacos y la presión intraocular posoperatoria a los 2 años fue de 16,5 mmHg. El índice total de éxito fue del 93,0 %. Conclusiones: La trabeculectomía permite un índice de éxito satisfactorio en el tratamiento del glaucoma avanzado en los pacientes estudiados.
ABSTRACT Introduction: Behavior in advanced stage glaucoma has brought controversies among specialists in ophthalmology due to its possible visual consequences. Objective: To evaluate the outcome of trabeculectomy surgery in patient treated with glaucoma in advanced stage. Method: An observational, descriptive, and longitudinal study of several cases was conducted at the Hospital General Docente "Dr. Juan Bruno Zayas Alfonso" in Santiago de Cuba, from 2015 through 2018. It was involved as total and selected 57 eyes with glaucoma in advanced stage and associated with a trabeculectomy surgery. Variables used were: age, sex, preoperative and postoperative variables used (number of drugs used for glaucoma management, best corrected visual acuity, visual field, measurement of intraocular pressure, and postoperative complications). Results: Average age was 65.4% and 55.8% were male. Preoperative and postoperative visual acuity in 54 eyes (96.5%) was the same. Antiglaucoma medication decreased to a median value of 1.6 drugs and the postoperative intraocular pressure, 2 years after surgery, was 16.5 mmHg. The overall success rate was 93.0%. Conclusions: Trabeculectomy had a satisfactory success rate in the patients with glaucoma in advanced stage treated.
RESUMO Introdução: O comportamento no glaucoma avançado é controverso entre os oftalmologistas devido às suas possíveis consequências visuais. Objetivo: Avaliar o resultado da trabeculectomia no tratamento de pacientes com glaucoma avançado. Método: No Hospital General Docente "Dr. Juan Bruno Zayas Alfonso" de Santiago de Cuba, durante o período 2015-2018, foi realizado um estudo observacional, descritivo e longitudinal de uma série de casos. O universo era formado por 57 olhos com glaucoma avançado operados pela técnica citada. As variáveis são descritas: idade, sexo, variáveis no período pré e pós-operatório (quantidade de medicamentos para controle do glaucoma, acuidade visual melhor corrigida, campo visual, medida da pressão intra-ocular, complicações pós-operatórias). Resultados: A média de idade foi de 65,4 anos, 55,8% eram homens. A acuidade visual pós-operatória foi igual à pré-operatória em 54 olhos (96,5%). A medicação antiglaucoma diminuiu para um valor médio de 1,6 medicamentos e a pressão intra-ocular pós-operatória em 2 anos foi de 16,5 mmHg. A taxa de sucesso total foi de 93,0%. Conclusões: A trabeculectomia permite uma taxa de sucesso satisfatória no tratamento do glaucoma avançado nos pacientes estudados.
Subject(s)
Humans , Male , Aged , Trabeculectomy , Glaucoma/diagnosis , Epidemiology, Descriptive , Longitudinal Studies , Observational StudyABSTRACT
Objective:To investigate the risk factors of pressure injury in patients with advanced cancer.Methods:100 patients with advanced malignant tumors who received treatment in The First People's Hospital of Huzhou from January to December 2019 were included in this study. After filling in data registration form, all patients received the first pressure injury risk assessment to assess their skin conditions within 2 hours after admission. At the same time, Karnofsky Performance Scale (KPS), Braden Scale score, serum albumin and hemoglobin levels were determined and assessed. Logistic multiple regression was used to analyze the correlation between various factors and stress injury.Results:Among the 100 patients, five patients had pressure injury. The incidence of hospital-acquired pressure injury was 5.00%. These five patients, consisting of three males (60.0%) and two females (40.00%), were aged 38-89 years. One (20%) patient had stage I pressure injury, three (60%) patients had type II pressure injury, and one (20.00%) patient had non staged injury. Pressure injury was compared between patients at different ages, with different Braden Scale scores, serum albumin and hemoglobin levels, KPS scores ( χ2 = 7.916, 34.657, 5.432, 18.034, 38.922, all P < 0.05). The incidence of pressure injury in patients aged ≥ 70 years with low serum albumin level, low hemoglobin level, KPS score ≤ 30 points, Braden Scale score ≤ 16 points was significantly higher than that in patients aged < 70 years with high serum albumin level, high hemoglobin level, KPS score > 30 points, Braden Scale score > 16 points ( χ2 = 18.034, 5.432, 7.916, 38.922, 34.657, all P < 0.05). Taking pressure injury as the dependent variable and a single factor as the independent variable, correlation analysis results revealed that low serum albumin level, low hemoglobin level, age ≥ 70 years, KPS score ≤ 30 points, Braden Scale score ≤ 16 points were independent risk factors for pressure injury in advanced cancer. Conclusion:KFS score, Braden scale score, serum albumin and hemoglobin levels are closely related to the occurrence of pressure injury in patients with advanced cancer. They are independent risk factors for pressure injury in patients with advanced cancer.
ABSTRACT
Laparoscopic gastrectomy (LG) has been proven to be safe and feasible and widely used in surgical treatment of early and advanced gastric cancer (AGC), which has advantages over open gastrectomy in intraoperative bleeding and postoperative recovery. Neoadjuvant chemo-therapy (NACT) could achieve the effect of tumor downstaging and provide more surgical treatment chances for patients with AGC, thus improving their prognosis. Feasibility of LG for patients with AGC after NACT is a crucial problem for surgeons. The authors review the relevant studies and conducte a Meta-analysis to evaluate the short-term efficacy of laparoscopic versus open gastrec-tomy in the treatment of AGC after NACT.
ABSTRACT
Gastric cancer is one of the most common malignant tumors in the world. China is still the country with the highest incidence of gastric cancer and most patients with gastric cancer are in locally advanced stage at the first diagnosis. Traditional radical surgery combined with post-operative adjuvant treatment is difficult to further improve the prognosis of patients. In recent years, the exploration and application of neoadjuvant treatment modes such as chemotherapy, radio-therapy, targeted therapy and immunotherapy in locally advanced gastric cancer have made continuous progress. However, there is still no consensus on the benefit population, regimen options, and efficacy evaluation of neoadjuvant therapy. The authors review and comb the research progress and controversy of neoadjuvant therapy for locally advanced gastric cancer.
ABSTRACT
Local advanced gastric cancer (LAGC) accounts for a large proportion of annual newly diagnosed gastric cancer patients in China. There is a general consensus for D2 radical gastrectomy followed by postoperative adjuvant chemotherapy for LAGC patients, and this therapeutic strategy has been confirmed by a series of clinical trials to obviously improve the patients' prognosis; however, the recurrence rate is still high (about 50%-80% in advanced stage), which makes it difficult to further improve the long-term survival. Perioperative therapy, especially whether preoperative neoadjuvant therapy (NAT) can improve the efficacy of patients with LAGC, has been paid more and more attention. NAT is mainly defined as a preoperative chemotherapy or chemoradiotherapy, aiming at increasing curative resection rate by downstaging tumor, eliminating micrometastases, and autologously testing of anti-cancer drug sensitivity etc. However, there are still some controversy whether LAGC patients could gain survival benefit from NAT and also lack of general consensus for this issue. In this paper, the author reviews and analyzes the current situation of perioperative therapies for LAGC patients, especially emphasize the results of neoadjuvant chemotherapy or chemoradiotherapy reported by various high-level clinical studies. The preliminary effect of perioperative chemotherapy combined with molecular targeted or immunotherapy has also aroused great interest and attention. While we continue to carry out NAT and look forward to more new high-level evidence trials on NAT, we must emphasize again that R0 gastrectomy remains the most important therapeutic modality for the patients with LAGC.
Subject(s)
Humans , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Chemoradiotherapy , Chemotherapy, Adjuvant , Combined Modality Therapy , Gastrectomy/methods , Lymph Node Excision , Neoadjuvant Therapy , Neoplasm Staging , Perioperative Care/trends , Stomach Neoplasms/therapyABSTRACT
Background: Chronic state of inflammation is an important factor in advanced cancer which is used by tumor cells for maintaining survival and growth. Hematological parameters such as neutrophil/lymphocyte ratio (NLR), thrombocyte/lymphocyte ratio (TLR), and lymphocyte/monocyte ratio (LMR) are reliable indicators of systemic inflammation. We aimed to elucidate the effect of hematological parameters and clinical features of patients on the prognosis of advanced-stage non-small cell lung cancer (NSCLC). Methods: We included 102 Stage IV NSCLC patients who presented to the oncology clinic between 2010 and 2016. Pretreatment clinical parameters and NLR, TLR, and LMR were retrieved from the medical records. The cutoff values, calculated with receiver operating curve analysis, for NLR, LMR, and TLR were 2.5, 3, and 183, respectively. All patients were divided into two groups according to cutoff values and analyzed accordingly. Results: Median overall survival and progression-free survival were 10 and 6 months, respectively. In univariate analysis, high NLR, high TLR, and low LMR were found to be significantly associated with survival. Among clinical parameters having eastern cooperative oncology group performance score 0–1, older age (≥70 years) single metastatic disease was prognostic. In multivariate Cox regression analysis, only the number of metastatic lesions and LMR were found to be independent predictors for survival. Conclusion: Among hematological parameters, only LMR was found to be an independent predictor of survival in patients with advanced-stage NSCLC
ABSTRACT
Background: Cervical cancer is a disease which claims maximum number of deaths in developing countries. Objective of this study was to understand the reason for delayed approach to medical help in women with advanced carcinoma cervix.Methods: It was a cross-sectional study. Information obtained from women with carcinoma cervix clinical stage IIb and above with proven histopathological diagnosis was recorded in the predetermined format.Results: Almost all the subjects were illiterate and were from lower socioeconomic strata and rural areas. None of them knew about the disease and its symptomatology. About 82% of the patients were symptomatic since 5-10 years however took no medical care during the period and 2/3rd of them even did not reveal their problem to any of the family members. About 79% of the subjects had never used any contraception and none had knowledge about its role in preventing infection. Majority of them (98%) had no idea about the role of PAP smear in screening carcinoma cervix. All of them said if they had knowledge about the disease, they would have sought medical help much earlier.Conclusions: The most important reason for delayed approach in our study was found to be lack of knowledge about the disease. Therefore, till such time that we have national screening program in place, these women who are at high risk of developing carcinoma of cervix should be targeted and educated through mass media so that these women could seek medical help in early stages.
ABSTRACT
@#With the progress of gene detection technology and the speed-up in new drug development, biological target therapy has fully covered the first-line treatment of advanced NSCLC. Immunotherapy has significantly improved the survival of advanced NSCLC patients with negative driven genes, and the median OS reaches about 2 years (15.6-30 months). EGFR is the most common driven gene. According to different EGFR mutation subtypes (L858R or 19del), different treatment mode (EGFR-TKI single drug, TKI combined with anti-vascular drugs and TKI combined with chemotherapy) is selected as the first-line treatment, which has become a consensus. Depending on the data of median PFS, the treatment efficacy against rare targets is more prominent, which has exceeded the efficacy of standard chemotherap:ALK (alectinib, PFS=34.8 months), ROS1 (ceritinib, PFS=19.3 months), RET (selpercatinib, PFS=18.4 months), BRAF (dabrafenib plus trametinib, PFS=14.6 months), NTRK (larotrectinib, PFS≥12 months) and MET (savolitinib, PFS=9.7 months). In conclusion, the first-line treatment of advanced NSCLC has entered the era of“precision-targeted treatment”based on different molecular typing, and it has become a consensus that high-throughput sequencing is required for newly diagnosed patients.
ABSTRACT
BACKGROUND@#Lung cancer is the most common cause of death in men in the world and in Indonesia where non-small cell carcinoma lung cancer (NSCLC) constitutes 85% of all lung cancer cases. The high mortality rate is due to a poor prognosis and is often diagnosed as having advanced stages. If it is known at the initial stage, the prognosis of lung cancer will be better. Prognosis can be predicted with a marker of prognostic biology, one of which is micro RNA (miRNA). This study aims to prove that serum miRNA can be predictive biological marker and prognosis in NSCLC patients in Indonesia.@*METHODS@#This study was cohort retrospective among 52 subjects in "Dharmais" Hospital National Cancer Center. Sample was obtained from patients' serum. MiR-34, miR-148, miR-155 and miR-222 serum are measured through Real-Time PCR (qPCR). Data were analyzed and interpreted with descriptive analysis, bivariate analysis (Mann Whitney-U for two type of variables or Kruskal-Wallis for more than two type of variables. Kaplan-Meier analysis was used to know association between characteristic which are sociodemographic, performance status, clinico-pathology, and survival rate in miRNA expression.@*RESULTS@#From this study, miRNA expression: miR-34 (46.15%), miR-148 (23.08%), miR-155 (40.38%) and miR-222 (32.69%). Performance status score was statistically significant correlation with miR-148 (P=0.049) and miR-222 (P=0.018). High miR-34 is associated with multiple M1b metastatic type (P=0.020), cancer cell type (adenocarcinoma, P=0.009) and adenocarcinoma epidermal growth factor receptor (EGFR) mutation (negative, P=0.031). There was a significant correlation between the high miR-222 as a poor prognosis in advanced stage NSCLC with M1b metastasis (Median Survival/MS: 27 d, P=0.049) and positive EGFR mutations (MS: 74 d, P=0.049) and correlation of miR-155 with adenocarcinoma (MS: 69 d, P=0.034) and positive EGFR gene mutations (MS: 58 d, P=0.023).@*CONCLUSIONS@#High miR-34 expression in advanced stage NSCLC is the predictive factor for multiple metastatic, adenocarcinoma cell type and adenocarcinoma negative EGFR mutation. High expression of miR-155 and miR-222 are poor prognoses, especially high miR-222 found in metastasis M1b and positive EGFR mutation and miR-155 found in adenocarcinoma and positive EGFR gene mutations. Further studies regarding correlation between miRNA and survival rate are needed.
ABSTRACT
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered.
ABSTRACT
Using the data of 139 ovarian cancer cases at our hospital, we investigated the effect of jingizai on prognosis when it was combined with standard therapy for ovarian cancer and prognosis by histopathological types. Combining jingizai with standard therapy was not effective in cases of stage I-II ovarian cancer, but it was effective in cases of stage III-IV ovarian cancer. Upon examination the effectiveness of jingizai according to histopathological types, we observed some improved prognosis in serous adenocarcinoma and mucinous adenocarcinoma cases ; however, prognosis didn't improve in endometrioid adenocarcinoma and clear cell adenocarcinoma. These results indicate that the effectiveness of combining jingizai with standard therapy may differ depending on histological type of ovarian cancer. When we investigated the difference between the distribution of histopathological types by cancer staging, we frequently found clear cell adenocarcinoma in stage I-II cancer cases. Also, serous adenocarcinoma and poorly differentiated adenocarcinoma had a high frequency among stage III-IV cancer cases. This difference may be the reason that the effectiveness of jingizai is different depending on the advances of each stage. However, no statistical difference was confirmed due to the small number of subjects analyzed. Analysis of larger sample size, which can be collected by performing collaborative studies with other facilities, will be required for more detailed investigation.
ABSTRACT
Objective@#To explore these adults′ perspective with filial piety and as well to elucidate adults′experience and filial caring behaviour whose parents were diagnosed as advanced cancer.@*Methods@#This is a qualitative study. A semi-structured and individual in-depth interview guide was designed and utilised to explore perspectives of 15 adults whose parents were diagnosed as advanced cancer. Thematic analysis method was adopted to analyse the data, which were synthesised into themes and subthemes.@*Results@#Three main themes were explicated: emotional experience, filial caring behaviours for parents and dilemmas and pressures. These adults adopted obedience, accompany, improving quality of life, completing parents’ wish to fulfil their commitment and filial piety during taking care of their cancer parents. However, they encountered ethical dilemmas regarding disclosure or non-disclosure cancer diagnosis to their parents.@*Conclusions@#Due to the profound influence of Chinese traditional culture, the adults whose parents were diagnosed as advanced cancer committed their filial caring behaviour to their parents very wholeheartedly and encountered difficulties and dilemmas. Therefore, oncology nurses are advised to share their love to cancer patients, to work with compassion and sympathy and support them by assisting with taking care of their patients, which in turn may facilitate their filial caring behaviours, decrease their pressure and negative emotions.
ABSTRACT
Gastric cancer is one of the most common clinical malignant tumors; surgery is an important treatment for it. The postoper-ative 5-year survival rate of patients with advanced gastric cancer is low; postoperative tumor recurrence is an important factor influ-encing the prognosis of patients. With the continuous development of domestic medicine, the technology of intraperitoneal hyper-thermic perfusion chemotherapy is improved continuously, and is widely used in postoperative adjuvant therapy for patients with ad-vanced gastric cancer. Long-term clinical practice shows that prophylactic use of hyperthermic intraperitoneal chemotherapy for ad-vanced gastric cancer could significantly reduce the recurrence rate of gastric cancer and improve the 5-year survival rate of patients. It plays a positive role in improving the quality of life of patients and overall clinical curative effect. In this review, the clinical applica-tion of hyperthermic intraperitoneal chemotherapy for advanced gastric cancer in China was summarized.
ABSTRACT
Objective To explore these adults′ perspective with filial piety and as well to elucidate adults′experience and filial caring behaviour whose parents were diagnosed as advanced cancer. Methods This is a qualitative study. A semi-structured and individual in-depth interview guide was designed and utilised to explore perspectives of 15 adults whose parents were diagnosed as advanced cancer. Thematic analysis method was adopted to analyse the data, which were synthesised into themes and subthemes. Results Three main themes were explicated: emotional experience, filial caring behaviours for parents and dilemmas and pressures. These adults adopted obedience, accompany, improving quality of life, completing parents’wish to fulfil their commitment and filial piety during taking care of their cancer parents. However, they encountered ethical dilemmas regarding disclosure or non-disclosure cancer diagnosis to their parents. Conclusions Due to the profound influence of Chinese traditional culture, the adults whose parents were diagnosed as advanced cancer committed their filial caring behaviour to their parents very wholeheartedly and encountered difficulties and dilemmas. Therefore, oncology nurses are advised to share their love to cancer patients, to work with compassion and sympathy and support them by assisting with taking care of their patients, which in turn may facilitate their filial caring behaviours, decrease their pressure and negative emotions.
ABSTRACT
@#To investigate whether postoperative therapy can bring survival benefits to patients with locally advanced esophageal squamous cell carcinoma who have received neoadjuvant chemotherapy with TP regimen. Methods We retrospectively reviewed clinical data of 115 patients with locally advanced esophageal squamous cell carcinoma who received neoadjuvant chemotherapy with TP regimen and underwent esophagectomy in our hospital from January 2007 through December 2016. Patients were divided into two groups including a non-receiving treatment group (54 patients with 47 males and 7 females) and a receiving treatment group (61 patients with 52 males and 9 females). There were 31 patients with postoperative chemotherapy, 14 with postoperative radiotherapy, and 16 with postoperative chemotherapy and radiotherapy in the receiving treatment group. Results In the non-receiving treatment group, the 5-year median disease free survival (DFS) rate was 54.7%, and the 5-year overall survival (OS) rate was 55.3%. In the receiving treatment group, the median DFS was 46.0 months (95% CI 22.9–69.1), the 5-year DFS rate was 42.3%; and the median OS was 68.0 months (95% CI 33.0–103.0), the 5-year OS rate was 51.3%. Furthermore, there was no statistical difference between the two groups with regards to DFS (P=0.641) or OS (P=0.757) using Kaplan-Meier method. Besides, in each subgroup, the results of Cox proportional hazard model analysis showed postoperative treatment did not improve survival (P>0.05, respectively). Conclusion Postoperative treatment does not bring survival benefits to patients with esophageal squamous cell carcinoma who have received neoadjuvant chemotherapy with TP regimen.
ABSTRACT
Resumen El alivio del sufrimiento existencial en los pacientes oncológicos en estadio avanzado es un objetivo terapéutico de primer orden. En el presente trabajo se sugieren una serie de ejes sobre los cuales podría pivotar la intervención psicoterapéutica, con el fin de propiciar: 1) la experiencia de que a pesar del "ya" de la situación límite, la vida "todavía" tiene sentido; 2) experiencias emocionales positivas que promuevan el bienestar y la calidad de vida; 3) el afrontamiento de la experiencia de enfermedad grave y de muerte esperada más o menos inminente, mediante el desarrollo de una actitud serena, reconciliada con la vida e integradora con uno mismo y con los demás, a la par que abierta a la trascendencia.
Abstract The relief of existential suffering in the patients with adavanced cancer is a first-order therapeutic goal. The present work suggests some axis on which psychotherapeutic intervention could be developed, in order to facilitate in these patients: 1) The experience of: In spite of the "existing" limited situation, one's life "still" has meaning, 2) Positive emotional experiences that promote well-being and quality of life, and 3) Face the serious illness that will cause one's almost imminent death, through the development of a serene, reconciled attitude with life and integrating with oneself and the others.
Resumo O alívio do sofrimento existencial em pacientes oncológicos em estágio avançado é um objetivo terapêutico de primeira ordem. No presente trabalho, sugerimos uma série de eixos nos quais a intervenção psicoterapêutica poderia girar, a fim de promover: 1) a experiência de que, apesar do "já" da situação limite, a vida "ainda" faz sentido; 2) experiências emocionais positivas, que promovam bem-estar e qualidade de vida; 3) enfrentar a experiência de doença grave e morte esperada mais ou menos iminente, através do desenvolvimento de uma atitude serena, conciliada com a vida e integrando-se consigo mesmo e com os outros, ao mesmo tempo que aberta à transcendência.